BioSpace News Archive

Boston is getting a new tenant focused on rare diseases. Italian pharma company Chiesi Farmaceutici S.p.A is launching a U.S.-based subsidiary Chiesi Global Rare Diseases with a focus on advancing research and new product development for rare and ultra-rare diseases.

Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.

Pharma and biotech companies strengthen their leadership teams and boards with this weeks appointments.

The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.

Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.

What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.

The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagnosed 30 hours after birth, apparently having gotten it from the mother.

One day after GlaxoSmithKline began to outline some of the broad strokes of splitting the company into two separate entities, more details are coming into place – particularly staffing concerns over the integration of the company’s vaccine business into its pharma operations.